Page 6 - Bluejay Diagnostics News Today

Wall Street analysts forecast that Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Rating) will report earnings per share of ($0.08) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Bluejay Diagnostics’ earnings. The firm is expected to report its next earnings results on Monday, January 1st. On average, analysts expect that […]

Brokerages expect Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Rating) to post ($0.08) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Bluejay Diagnostics’ earnings. The company is expected to issue its next quarterly earnings report on Monday, January 1st. According to Zacks, analysts expect that Bluejay Diagnostics […]

Zacks Investment Research upgraded shares of Bluejay Diagnostics (NASDAQ:BJDX – Get Rating) from a hold rating to a buy rating in a report released on Monday morning, Zacks.com reports. Zacks Investment Research currently has $1.25 target price on the stock. According to Zacks, “Bluejay Diagnostics Inc. is a late-stage, pre-revenue medical device company. It focused […]

Bluejay Diagnostics, Inc. today reported that it has completed 90 subjects in the prospective multicenter clinical study addressing rapid IL-6 test for COVID-19 patients with critical care.

If you’re willing to absorb massive risk for the chance of significant upside, these low-float penny stocks could fit the bill.

Numerous technologies in development to help with the diagnosis of sepsis have a singular objective ─ detect the condition as quickly as possible.

Numerous technologies in development to help with the diagnosis of sepsis have a singular objective ─ detect the condition as quickly as possible.